5667 related articles for article (PubMed ID: 23106051)
21. Comparison of whole-body versus limited whole-body 18F-FDG PET/CT scan in malignant cutaneous melanoma.
Lazaga FJ; Oz OK; Adams-Huet B; Anderson J; Mathews D
Clin Nucl Med; 2013 Nov; 38(11):882-4. PubMed ID: 24096999
[TBL] [Abstract][Full Text] [Related]
22. Role of limited whole-body PET/CT in pediatric lymphoma.
Sammer MB; Shulkin BL; Alessio A; Parisi MT
AJR Am J Roentgenol; 2011 May; 196(5):1047-55. PubMed ID: 21512070
[TBL] [Abstract][Full Text] [Related]
23. Clinical relevance of 18F-FDG PET/CT lower-limb imaging in patients with malignant cutaneous melanoma.
Plouznikoff N; Arsenault F
Nucl Med Commun; 2017 Dec; 38(12):1103-1108. PubMed ID: 28885538
[TBL] [Abstract][Full Text] [Related]
24. Utility of whole-body (head-to-toe) PET/CT in the evaluation of melanoma and sarcoma patients.
Webb HR; Latifi HR; Griffeth LK
Nucl Med Commun; 2018 Jan; 39(1):68-73. PubMed ID: 29189489
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T
J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438
[TBL] [Abstract][Full Text] [Related]
26. 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact.
Stas M; Stroobants S; Dupont P; Gysen M; Hoe LV; Garmyn M; Mortelmans L; Wever ID
Melanoma Res; 2002 Oct; 12(5):479-90. PubMed ID: 12394190
[TBL] [Abstract][Full Text] [Related]
27. Value of true whole-body FDG-PET/CT scanning protocol in oncology: optimization of its use based on primary diagnosis.
Sebro R; Mari-Aparici C; Hernandez-Pampaloni M
Acta Radiol; 2013 Jun; 54(5):534-9. PubMed ID: 23463863
[TBL] [Abstract][Full Text] [Related]
28. Detection of unexpected additional primary malignancies with PET/CT.
Ishimori T; Patel PV; Wahl RL
J Nucl Med; 2005 May; 46(5):752-7. PubMed ID: 15872346
[TBL] [Abstract][Full Text] [Related]
29. Multimodality approach of perioperative 18F-FDG PET/CT imaging, intraoperative 18F-FDG handheld gamma probe detection, and intraoperative ultrasound for tumor localization and verification of resection of all sites of hypermetabolic activity in a case of occult recurrent metastatic melanoma.
Povoski SP; Hall NC; Martin EW; Walker MJ
World J Surg Oncol; 2008 Jan; 6():1. PubMed ID: 18186915
[TBL] [Abstract][Full Text] [Related]
30. Verification of musculoskeletal FDG-PET-CT findings performed for melanoma staging.
Mansour AA; Kelley MC; Hatmaker AR; Holt GE; Schwartz HS
Ann Surg Oncol; 2010 Apr; 17(4):1144-51. PubMed ID: 19967460
[TBL] [Abstract][Full Text] [Related]
31. Whole-Body versus Routine Skull Base to Mid-thigh
Ozdemir S; McCook B; Klassen C
J Clin Imaging Sci; 2020; 10():47. PubMed ID: 32874752
[TBL] [Abstract][Full Text] [Related]
32. Brain metastases detectability of routine whole body (18)F-FDG PET and low dose CT scanning in 2502 asymptomatic patients with solid extracranial tumors.
Bochev P; Klisarova A; Kaprelyan A; Chaushev B; Dancheva Z
Hell J Nucl Med; 2012; 15(2):125-9. PubMed ID: 22741148
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: validation by whole body FDG-PET and conventional diagnostics.
Mruck S; Baum RP; Rinne D; Hör G
Anticancer Res; 1999; 19(4A):2685-90. PubMed ID: 10470220
[TBL] [Abstract][Full Text] [Related]
34. 18F-FDG PET/CT of patients with cancer: comparison of whole-body and limited whole-body technique.
Osman MM; Chaar BT; Muzaffar R; Oliver D; Reimers HJ; Walz B; Nguyen NC
AJR Am J Roentgenol; 2010 Dec; 195(6):1397-403. PubMed ID: 21098201
[TBL] [Abstract][Full Text] [Related]
35. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison.
Agress H; Cooper BZ
Radiology; 2004 Feb; 230(2):417-22. PubMed ID: 14699176
[TBL] [Abstract][Full Text] [Related]
36. Clinical Impact of FDG PET/CT of the Lower Extremities in Patients With Merkel Cell Carcinoma With Primary Disease Site Outside of the Lower Extremities.
Ishiyama M; Behnia F; Vesselle H
AJR Am J Roentgenol; 2021 Mar; 216(3):776-780. PubMed ID: 33474987
[No Abstract] [Full Text] [Related]
37. [The role of PET scan in the diagnosis of malignant melanoma].
Hunyadi J; Szakáll S; Gilde K; Bégány A; Esik O; Trón L; Galuska L; Ocsai H; Török L
Orv Hetil; 2002 May; 143(21 Suppl 3):1272-5. PubMed ID: 12077913
[TBL] [Abstract][Full Text] [Related]
38. Utility of preoperative [(18)]f fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients.
Brady MS; Akhurst T; Spanknebel K; Hilton S; Gonen M; Patel A; Larson S
Ann Surg Oncol; 2006 Apr; 13(4):525-32. PubMed ID: 16474909
[TBL] [Abstract][Full Text] [Related]
39. A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.
Beasley GM; Parsons C; Broadwater G; Selim MA; Marzban S; Abernethy AP; Salama AK; Eikman EA; Wong T; Zager JS; Tyler DS
Ann Surg; 2012 Aug; 256(2):350-6. PubMed ID: 22691370
[TBL] [Abstract][Full Text] [Related]
40.
Lawal I; Lengana T; Ololade K; Boshomane T; Reyneke F; Modiselle M; Vorster M; Sathekge M
Nuklearmedizin; 2017 Jun; 56(3):83-89. PubMed ID: 28154879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
